Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB19055 in Uncontrolled and Resistant Hypertension
NCT07833098Phase 2Not yet recruiting
- Sponsor
- Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VB19055 in hypertension (HTN) and resistant hypertension (RH) (4 arms), sponsored by Shenzhen Yangli Pharmaceutical Technology Co. Ltd. Primary endpoint: Change from baseline in seated clinic systolic blood pressure at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
VB19055
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on NCT07833098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07833098.